NEW YORK, May 17, 2005 (PRIMEZONE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), announced today that Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview of the Company, including recent clinical results and upcoming milestones at the Banc of America Securities Annual Health Care Conference in Las Vegas, NV. Mr. Weiss' presentation will take place tomorrow, Wednesday, May 18, 2005 at 4:40 p.m. Pacific Time in Four Seasons Ballroom 2 of the Four Seasons Hotel. A live audio webcast of Mr. Weiss' presentation will be available at http://www.veracast.com/webcasts/bas/healthcare05/id21213296.cfm. An archived version of the webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound for the treatment of diabetic nephropathy, which is in a Phase 2 clinical program and for which a pivotal Phase 3 and Phase 4 program is pending commencement under an SPA with the FDA. Additionally, Keryx is developing clinical- stage oncology compounds, including KRX-0401, a novel, first-in-class, oral modulator of Akt and other important signal transduction pathways, which is in Phase 2 clinical development. Keryx also has an active in-licensing and acquisition program designed to identify and acquire clinical-stage drug candidates. Keryx Biopharmaceuticals is headquartered in New York City.